EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

L Gossec, X Baraliakos, A Kerschbaumer… - Annals of the …, 2020 - ard.bmj.com
Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …

Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis

B Hagège, E Tan, M Gayraud, B Fautrel… - …, 2020 - academic.oup.com
Objectives Remission (REM) or low disease activity (LDA) is the treatment target in psoriatic
arthritis (PsA). The objective of this study was to assess the reporting and prevalence of …

PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials

AM Orbai, R Holland, YY Leung, W Tillett… - The Journal of …, 2019 - jrheum.org
Objective. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) and Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) …

Determinants of patient‐reported psoriatic arthritis impact of disease: an analysis of the association with sex in 458 patients from fourteen countries

AM Orbai, J Perin, C Gorlier, LC Coates… - Arthritis care & …, 2020 - Wiley Online Library
Objective Sex differences may modify symptoms, disease expression, and treatment effects.
The objective of this study was to evaluate the link between life impact and sex in psoriatic …

Association of pain sensitization and conditioned pain modulation to pain patterns in knee osteoarthritis

LC Carlesso, LF Law, N Wang, M Nevitt… - Arthritis care & …, 2022 - Wiley Online Library
Objective To examine the cross‐sectional association of ascending pain mechanisms,
implicated in pain sensitization, and descending pain modulation with pain patterns and …

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

L Tucker, A Allen, D Chandler, C Ciurtin, A Dick… - …, 2022 - academic.oup.com
Background PsA is a chronic, inflammatory, musculoskeletal disease affecting
approximately one quarter of people with the skin condition psoriasis [1, 2]. PsA is a highly …

Treat-to-target in PsA: methods and necessity

E Dures, S Shepperd, S Mukherjee, J Robson… - RMD open, 2020 - rmdopen.bmj.com
With increasing recognition of the high burden and impact of psoriatic arthritis (PsA) and the
growing number of therapeutic options, there has been an intensifying focus on treatment …

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices

E Lubrano, S Scriffignano, AB Azuaga, J Ramirez… - RMD open, 2020 - rmdopen.bmj.com
Objective The aim of this study was to evaluate the discriminant capability of the Patient
Acceptable Symptom State (PASS) according to disease activity, remission/low disease …

Impact of comorbidities on disease activity, patient global assessment, and function in psoriatic arthritis: a cross-sectional study

E Lubrano, S Scriffignano, AB Azuaga… - Rheumatology and …, 2020 - Springer
Introduction The aim of this study was to evaluate the impact of comorbidities on disease
activity, patient's impact of the disease, patient global assessment, and function in psoriatic …

Performance of the ASAS health index for the evaluation of spondyloarthritis in daily practice

S Alonso-Castro, E Pardo, L Charca, M Pino… - The Journal of …, 2020 - jrheum.org
Objective The Assessment of SpondyloArthritis international Society Health Index (ASAS HI)
is a tool designed to assess disease impact in spondyloarthritis (SpA), but its clinical …